SPRY vs. RARE, HCM, PBH, CORT, MRUS, BHVN, FOLD, XENE, ARWR, and PTCT
Should you be buying ARS Pharmaceuticals stock or one of its competitors? The main competitors of ARS Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), Merus (MRUS), Biohaven (BHVN), Amicus Therapeutics (FOLD), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
Ultragenyx Pharmaceutical (NASDAQ:RARE) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 5.8% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Ultragenyx Pharmaceutical received 800 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. Likewise, 77.14% of users gave Ultragenyx Pharmaceutical an outperform vote while only 71.43% of users gave ARS Pharmaceuticals an outperform vote.
ARS Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -138.58%. Ultragenyx Pharmaceutical's return on equity of -21.14% beat ARS Pharmaceuticals' return on equity.
Ultragenyx Pharmaceutical has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.
In the previous week, Ultragenyx Pharmaceutical had 18 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 20 mentions for Ultragenyx Pharmaceutical and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.76 beat Ultragenyx Pharmaceutical's score of 0.57 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.
Ultragenyx Pharmaceutical currently has a consensus price target of $90.67, suggesting a potential upside of 125.88%. ARS Pharmaceuticals has a consensus price target of $18.50, suggesting a potential upside of 108.33%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than ARS Pharmaceuticals.
ARS Pharmaceuticals has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Ultragenyx Pharmaceutical and ARS Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get ARS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARS Pharmaceuticals Competitors List
Related Companies and Tools
